Notice: This company has been marked as potentially delisted and may not be actively trading. Paratek Pharmaceuticals (PRTK) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Paratek Pharmaceuticals Announces Completion of U.S. Onshoring Program, Making NUZYRA® (omadacycline) the Only Novel Antibiotic with Domestic Supply and Manufacturing CapabilitiesNovember 14 at 9:00 AM | globenewswire.comParatek Pharmaceuticals Announces Positive Top-Line Data from Phase 2b Study of Oral Omadacycline (OMC) in Nontuberculous Mycobacterial (NTM) Abscessus Pulmonary DiseaseNovember 8, 2024 | globenewswire.comParatek Pharmaceuticals Announces Presentation of Several New Studies of NUZYRA® (omadacycline) Across a Range of Serious Infections at IDWeek 2024October 14, 2024 | globenewswire.comParatek Pharmaceuticals Completes Five-Year Microbiologic Surveillance Study of NUZYRA® (omadacycline) Demonstrating No Change in In Vitro Potency Against Indicated PathogensJuly 31, 2024 | globenewswire.comParatek Pharmaceuticals Announces Positive Top-line Efficacy and Safety Data from Post-Marketing Study of NUZYRA® (omadacycline) for Patients with Moderate to Severe Community-Acquired Bacterial PneumoniaJuly 18, 2024 | globenewswire.comParatek Reports Positive Data For Nuzyra As Post-exposure Prophylaxis Of Pulmonary Anthrax In NHPsMarch 5, 2024 | markets.businessinsider.comMira Pharmaceuticals Stock (NASDAQ:MIRA) Dividends: History, Yield and DatesFebruary 24, 2024 | benzinga.comParatek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023October 5, 2023 | finance.yahoo.comNovo Holdings closes $462 mln acquisition of Paratek PharmaceuticalsSeptember 21, 2023 | finance.yahoo.comGurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.September 21, 2023 | finance.yahoo.comTrading was temporarily halted for "PRTK" at 07:09 PM with a stated reason of "News pending."September 21, 2023 | marketbeat.comParatek Pharmaceuticals, Inc. (NASDAQ:PRTK) is definitely on the radar of institutional investors who own 48% of the companySeptember 19, 2023 | finance.yahoo.comParatek Pharmaceuticals shareholders approve $462M buyout dealSeptember 18, 2023 | bizjournals.comParatek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/SSeptember 18, 2023 | finance.yahoo.comSecond Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/SSeptember 12, 2023 | finance.yahoo.comLeading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo HoldingsSeptember 7, 2023 | finance.yahoo.comAcadian Asset Management LLC Sells 107,287 Shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)Acadian Asset Management LLC reduced its stake in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK - Free Report) by 43.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 139,386 shares of the specialty pharmaceuSeptember 7, 2023 | marketbeat.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TRTN, AMED, PRTKAugust 10, 2023 | benzinga.comHC Wainwright Comments on Paratek Pharmaceuticals, Inc.'s Q3 2023 Earnings (NASDAQ:PRTK)Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK - Free Report) - Equities research analysts at HC Wainwright cut their Q3 2023 earnings per share estimates for Paratek Pharmaceuticals in a report released on Monday, August 7th. HC Wainwright analyst E. Arce now expects that the specialty pharmaceuticaAugust 9, 2023 | marketbeat.comH.C. Wainwright Keeps Their Hold Rating on Paratek Pharmaceuticals (PRTK)August 7, 2023 | markets.businessinsider.comNews Flash: Analysts Just Made A Captivating Upgrade To Their Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) ForecastsAugust 4, 2023 | finance.yahoo.comCarlyle Group Inc. Takes Position in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)Carlyle Group Inc. purchased a new stake in shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK - Free Report) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 1,041,131 shares of the specialty pharmaceAugust 4, 2023 | marketbeat.comParatek Pharmaceuticals Files Definitive Proxy Statement and Letter to Stockholders in Connection with Acquisition by Gurnet Point Capital and Novo HoldingsAugust 3, 2023 | finance.yahoo.comParatek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 MillionAugust 3, 2023 | finance.yahoo.comPRTK Paratek Pharmaceuticals, Inc.July 27, 2023 | seekingalpha.comNexPoint Sends Demand Letter for Books and Records to Paratek Pharmaceuticals in Connection with Proposed Acquisition by Gurnet Point CapitalJuly 11, 2023 | finance.yahoo.comHC Wainwright & Co. Reiterates Paratek Pharmaceuticals (PRTK) Neutral RecommendationJuly 11, 2023 | msn.comH.C. Wainwright Reaffirms Their Hold Rating on Paratek Pharmaceuticals (PRTK)July 10, 2023 | markets.businessinsider.comParatek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary AnthraxJuly 10, 2023 | finance.yahoo.comParatek Pharmaceuticals (PRTK) Price Target Decreased by 41.87% to 3.16July 6, 2023 | msn.comParatek Pharmaceuticals (NASDAQ:PRTK) Earns Hold Rating from Analysts at StockNews.comStockNews.com began coverage on shares of Paratek Pharmaceuticals in a research note on Friday. They set a "hold" rating on the stock.June 30, 2023 | marketbeat.comParatek antibiotic Nuzyra to receive EU orphan drug statusJune 27, 2023 | msn.comParatek investor NexPoint warns it may vote against takeover dealJune 27, 2023 | msn.comParatek Pharmaceuticals Acknowledges Receipt of NexPoint LetterJune 27, 2023 | finance.yahoo.comNexPoint Asset Management Sends Open Letter to the Board of Paratek Pharmaceuticals Regarding Upcoming Annual Meeting and Proposed Acquisition by Gurnet Point CapitalJune 27, 2023 | finance.yahoo.comEuropean Medicines Agency COMP Recommends Positive Opinion on Orphan Medicinal Product Designation for NUZYRA® (omadacycline) for Treatment of Nontuberculous Mycobacterial (NTM) Lung DiseaseJune 27, 2023 | finance.yahoo.comParatek Pharmaceuticals plans to go private in $462M dealJune 12, 2023 | bizjournals.comParatek Pharmaceuticals Presenting New Data from NUZYRA® (omadacycline) and Investigator-Initiated Research Programs at ASM Microbe 2023June 12, 2023 | finance.yahoo.comPRTK Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Paratek Pharmaceuticals, Inc. Is Fair to ShareholdersJune 11, 2023 | businesswire.comThe Petri Dish: Startup chaired by Vertex founder raises $150M, Paratek to go private in $462M dealJune 8, 2023 | bizjournals.comJefferies Downgrades Paratek Pharmaceuticals (PRTK)June 7, 2023 | msn.comH.C. Wainwright downgrades Paratek Pharmaceuticals (PRTK) to a HoldJune 7, 2023 | markets.businessinsider.comWhy Paratek Pharmaceuticals Stock Is Up TodayJune 6, 2023 | benzinga.comParatek Pharmaceuticals Agrees To Be Taken Private By Gurnet Point And Novo Holdings For $462MJune 6, 2023 | msn.comParatek Pharmaceuticals Shares Rise on Deal to Go Private >PRTKJune 6, 2023 | marketwatch.comParatek Pharmaceuticals to Be Acquired in Deal Worth Up to $462 Million >PRTKJune 6, 2023 | marketwatch.comParatek Pharmaceuticals to be taken private in deal worth up to $462MJune 6, 2023 | msn.comParatek Pharmaceuticals to be Acquired by Gurnet Point Capital and Novo HoldingsJune 6, 2023 | finance.yahoo.comTrading was temporarily halted for "PRTK" at 08:06 AM with a stated reason of "News pending."June 6, 2023 | marketbeat.comParatek Pharamceuticals jumps amid report about takeover interestJune 1, 2023 | msn.com Get Paratek Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTK and its competitors with MarketBeat's FREE daily newsletter. Email Address 3 Dirt-Cheap Stocks You Can’t Afford to Ignore (Ad)Often, investors will overlook stocks just because they're cheap. It's a common thought that a cheap price tag means that something must be wrong with the company. But this couldn't be further from the case in many instances. Get your FREE look at these THREE companies right here. PRTK Media Mentions By Week PRTK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRTK News Sentiment▼0.000.54▲Average Medical News Sentiment PRTK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRTK Articles This Week▼20▲PRTK Articles Average Week Get Paratek Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Kezar Life Sciences News Today Hookipa Pharma News Today NextCure News Today Unity Biotechnology News Today Nektar Therapeutics News Today Omeros News Today Assembly Biosciences News Today Cumberland Pharmaceuticals News Today Theravance Biopharma News Today Eli Lilly and Company News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRTK) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredThis small cap’s electric marine powertrain broke the world speed recordThe future of marine propulsion has arrived-powered by a $2 billion powerhouse. In collaboration with McLar...The Tomorrow Investor | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredElon Musk has put himself in their crosshairsToday, I have another controversial prediction. One which I will take no pleasure in seeing come true. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Paratek Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Paratek Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
